Chat with us, powered by LiveChat

Loading...

Non-Small Cell Lung Cancer Treatment Market Report

RA00123

Non-Small Cell Lung Cancer Treatment Market, by Treatment Type (Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy), by Drug (Carboplatin, Fluorouracil, Cyclophosphamide, Doxorubicin, Cisplatin), Regional Analysis (North America, Europe, Asia-Pacific, LAMEA) – Global Opportunity Analysis and Industry Forecast, 2019–2026

RA00123

Pages: NA

Feb 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Non-Small Cell Lung Cancer Treatment Market

Global Non-Small Cell Lung Cancer Treatment Market Overview 2026:

Lung cancer can be bifurcated into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer is the unrestrained growth of numerous cells in lung tissues. The most common type of lung cancer cases registered is non-small cell lung cancer. The most commonly observed symptoms of NSCLC are loss of appetite, chest pain, wheezing, weight loss, hoarseness, shortness of breath, coughing up blood, recurring bronchitis, and fatigue among others. Increasing incidences of lung cancer cases are caused due to air pollution, owing to the inhalation of harmful metals such as cadmium and radon, HIV infection, smoking, and rapid growth in the population are some of the key factors driving the non-small cell lung cancer treatment market during the forecast period.

Market Drivers: Government initiatives to control pollution and smoking are anticipated to drive the market growth during the projected period

The non-small cell lung cancer treatment market is expected to witness swift growth majorly due to rising awareness about the disease among people globally. In addition, stringent government regulations to control reasons for the cancer occurrences, for instance, smoking control regulations and others is expected to drive the market growth during the projected period. These key factors will act as a substantial factor for the growth of the global non-small cell lung cancer treatment market over the forecasted period. Furthermore, rapid authorizations of various drugs such as Carboplatin, Fluorouracil, and others for curing non-small cell lung cancer will further upsurge the market growth.

Approval of various drugs for the treatment of lung cancer is expected to create greater opportunities in the near future

Inspite of the efficiency of numerous targeted treatments, the drugs utilized for the therapies are in their research and development stages. The market is expected to reach newer heights once the regulations, approvals, and clinical trials for these upcoming drugs are accomplished. 

Limited treatment options for non-small cell lung cancer treatment is expected to restrain the market growth

The limitations related to treatment, and the availability of generic drugs are anticipated to hamper the market growth during the projected period. Moreover, rising resistance towards targeted therapies will cause a restriction in the development of global non-small cell lung cancer treatment market during the forecasted period.

Surgery segment is anticipated to lead the Global Non-Small Cell Lung Cancer Treatment Market in 2018

The global non-small cell lung cancer treatment market, on the basis of treatment type, has been categorized into chemotherapy, surgery, radiation therapy and targeted therapy. Surgery is mainly chosen for treating patients in their first two phases of non-small cell lung cancer treatment. This includes pneumonectomy, lobectomy, and wedge resection. Chemotherapy is widely preferred for a large number of patients suffering from lung cancer. As per the guidelines laid by the American Society for Clinical Oncology (ASCO), the usage of platinum combination therapy must be considered for treating the first phase of non-small cell lung cancer treatment. For chemotherapy, cisplatin and carboplatin are used according to the approvals from the U.S. FDA.

Asia-Pacific region will have enormous opportunities for the market investors to grow over the coming years

North America region is expected to dominate the global non-small lung cancer treatment market. The growth is majorly attributed to the presence of a large number of developed healthcare infrastructure and key players in this region. Satisfactory insurance policies, for instance, reimbursement for the majority of medical treatments, along with the existence of regulatory bodies and key research is anticipated to drive the North American market during the projected period.  

Non-small cell lung cancer treatment market for Asia-Pacific region is anticipated to experience a swift growth in the near future. Rising incidences of numerous cancers, along with vast unmet medical needs, will likely create new growth opportunities for the adoption of non-small cell lung cancer treatments at a swift growth rate. Increasing government initiatives in developing nations such as South Korea, China, and India to improve the awareness regarding cancer diseases among the people is anticipated to further propel the Asia Pacific non-small cell lung cancer treatment market.

To explore more about Non-Small Cell Lung Cancer Treatment Market, get in touch with our analysts here. https://www.researchdive.com/connect-to-analyst/123

Key players in the Non-Small Cell Lung Cancer Treatment Market:

Product development and joint ventures are the most common strategies followed by the market players


Key players in the Non-Small Cell Lung Cancer Treatment Market

Source: Research Dive Analysis

The key players for the global non-small cell lung cancer treatment market are GlaxoSmithKline PLC, Astra Zeneca PLC, Genentech Inc., Pfizer Inc., Bristol-Myers Squibb, Celgene Corp., Eli Lilly & Co., Sun Pharmaceutical Industries Ltd., and Boehringer Ingelheim are some of the key players in this market. These key players are majorly concentrating growth advancements in current technology, new product launches, mergers and acquisitions, and geographical expansion. These are some of the growth strategies adopted by these companies.
For instance, in August 2018, U.S. FDA sanctioned the Keytruda-chemotherapy combination for the treatment of non-squamous non-small cell lung cancer that was developed by Merck. 

 

Aspect

Particulars

  Historical Market Estimations

  2018-2019

  Base Year for Market Estimation

  2018

  Forecast timeline for Market Projection

  2019-2026

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Treatment

  • Surgery

  • Chemotherapy

  • Radiation Therapy

  Segmentation by Drug

  • Carboplatin

  • Fluorouracil

  • Cyclophosphamide

  • Doxorubicin

  • Cisplatin

  Key Countries Covered

U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia

  Key Companies Profiled

  • GlaxoSmithKline plc.

  • Astra Zeneca PLC

  • Genentech Inc.

  • Pfizer Inc.

  • Bristol Squibb

  • Celgene Corp

  • Eli Lilly & Co.,

  • Sun Pharmaceutical Industries Ltd.,

  • Boehringer Ingelheim

  • Merck

Source: Research Dive Analysis


FREQUENTLY ASKED QUESTIONS?
 

A. Sun Pharmaceutical, Eli Lilly & Co., and Bristol Squibb are some of the key players in the global Non-Small Cell Lung Cancer Treatment Market.

A. Asia-Pacific possesses great investment opportunities for investors to witness the most promising growth in the coming years.

A. Product development and joint ventures are the key strategies opted by the operating companies in this market.

A. Genetech Inc. and GlaxoSmithKline plc are investing more in R&D activities for developing new products and technologies.

Research Methodology

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed